Merck Serono has announced plans to appeal against the European Medicines Agency’s decision not to recommend approval of its candidate multiple sclerosis drug, Movectro (cladribine). The negative opinion was issue on 23 September 2010. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
